Loss-making quarter masks EU-GMP bet; profitability path unproven

₹94.2 Cr revenue (+31.2% YoY), but profit swung to ₹-4.0 Cr loss (vs -₹1.9 Cr prior year)

EBITDA margin collapsed to 3.7% (₹34 Cr) vs prior year ~6-7%; NPM -4.2% (loss-making)

58.1% gross margin is 1 in 5-year outlier; management admits it is product-mix driven, expects to normalize to 55-58% range

Draft report received (no critical observations), but final report still pending as of call date 07-Aug; CAPA yet to be submitted

Guidance is contingent: 60-70% of growth dependent on EU-GMP; assumes 8-10 MAs grant and 2-quarter ramp. Q1 loss and 3.7% EBITDA margin suggest execution risk

Prior call (FY26) implied 'substantial completion of remediation' by FY27; call now reveals draft report only just received, final report 2+ weeks away, CAPA 2-3 months. Ramp now Q4 FY27, not Q2-Q3 as timeline suggested.

Q1 FY27 PAT -₹4.0 Cr vs -₹1.9 Cr Q1 FY26 (loss widened 114% YoY). EBITDA margin 3.7% vs 6-7% prior year. Employee costs, consulting, and EU-GMP expenses cited.

Implies ~₹410-420 Cr FY27 (analyst math: Q1 ₹94.2 × 4.4x typical multiplier). Without EU-GMP, growth is mid-single-teens, not the 20%+ prior tone suggested.

Management now explicit: FY27 EBITDA margins ~similar to last year (mid-single-digit); mid-teens margins only in FY28 post-EU-GMP + supply ramp. ROE concern (currently ~2%) flagged by analyst but addressed only with multi-year recovery rhetoric.

Draft report received. Final report expected 'within 2 weeks.' Post-final, CAPA submission within 2-3 months. Supplies expected Q4 FY27.

₹1.82 Cr one-time (TGA audit, EU-GMP consulting, MIDC charges). Rest is normalized. Employee costs now ₹19 Cr quarterly run-rate (post-hiring complete).

Margins impacted by planned investments (staff, consulting). Once revenue exceeds ₹100 Cr and operating leverage kicks in, margins recover. Post-EU-GMP, expect mid-teens to ₹500 Cr+.

This is a long-term play. Once EU-GMP comes and regulated market revenue scales, margins will improve. R&D investment is the DNA of the company.

60-70% of growth from EU-GMP. Base business and R&D growing steady levels, but major jump from EU.

Filing stage takes ~210 days; queries from authorities cause delays. We're nearing end of regulatory clock. All queries answered. MAs to come once EU-GMP is approved.

CAPA submitted; assessor reviewing. Expect certification in coming months. Already received one order; supplies to start in 2-3 months.

Only 2-3 players in India. In Europe, very few with GMP-certified facilities. We'll be one of few with approvals for sildenafil/Rizatriptan in Europe—competitive edge.

Yes, we have an alternate site with batches under stability. Once stability completes, we can supply from there as risk measure. But primary strategy remains in-house manufacturing.

MAs have been filed; we're near end of 210-day regulatory clock. All queries answered. EU-GMP is the only blocker. Once approved, MAs will be granted.

Saw some impact in Q1; now regularizing. If situation worsens, could impact further, but right now normalizing.

Implies ₹410-420 Cr full-year. Driven by formulation expansion, base business growth, and emerging market traction (Australia, R&D B2B).

Highly contingent: EU-GMP approval timing (expected Aug-Oct 2026), MA grant (2-3 months post), and customer ramp (assumed 2 quarters lag). 60-70% attributed to EU; rest to base growth.

Cost increases (₹19 Cr/quarter employee run-rate) offset by gross margin and operating leverage. No material margin improvement until revenue >₹100 Cr.

Dependent on 30-35% revenue growth and volume absorption of fixed costs. No specific margin target quantified; analyst consensus suggested 13-14% at ₹500 Cr scale.

Majority of historical CapEx completed; only upgrades and maintenance remaining this year.

EU-GMP final report pending; CAPA review 2-3 months thereafter. Any adverse observations could extend timeline. Entire 30-35% FY28 growth guidance depends on Aug-Oct 2026 approval window; miss would delay revenue by 6+ months.

Q1 FY27 PAT -₹4.0 Cr despite 31% revenue growth; NPM -4.2%. Company is destroying shareholder value in near term; ROE ~2% vs cost of capital 10%. Margin recovery dependent on multi-year EU-GMP ramp and scaling.

12 NIP/OTF products in pipeline for 3-4 quarters with no visible progress. Even if MAs granted post-EU-GMP, ramp speed to 30-35% growth (60-70% EU-dependent) is unproven. Manufacturing partnerships (alternate sites) add complexity.

Exports 84% of operating income. Q1 saw MENA geopolitical impact. While now 'regularizing,' escalation could materially reduce top-line. Primarily uncontrollable.

Total debt ₹145 Cr as of 30-Jun-2026. Operating cash flow weak due to elevated debtors (~100 days) and inventory buildup. Interest coverage thin given low profitability; loss-making Q1 raises debt serviceability concerns.